Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered With and Without an Adjuvant Patch in Healthy Adults

Next Previous
Trial Profile

A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Administered With and Without an Adjuvant Patch in Healthy Adults

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KD 295 (Primary) ; Heat-labile enterotoxin E coli
  • Indications Influenza A virus H5N1 subtype; Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors Intercell USA; Valneva USA

Most Recent Events

  • 11 Dec 2017 According to a Valneva media release, Intercell USA changed its name to Valneva USA.
  • 09 Sep 2008 Planned end date changed from 1 Apr 2008 to 1 Jun 2008, according to ClinicalTrials.gov.
  • 07 Sep 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top